Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 171,369
  • Shares Outstanding, K 112,743
  • Annual Sales, $ 7,570 K
  • Annual Income, $ -94,310 K
  • 60-Month Beta 1.72
  • Price/Sales 25.32
  • Price/Cash Flow N/A
  • Price/Book 1.92
Trade ARDX with:

Options Overview Details

View History
  • Implied Volatility 243.48%
  • Historical Volatility 168.82%
  • IV Percentile 93%
  • IV Rank 40.39%
  • IV High 507.68% on 11/22/21
  • IV Low 64.46% on 01/25/21
  • Put/Call Vol Ratio 0.10
  • Today's Volume 27,196
  • Volume Avg (30-Day) 11,269
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 98,787
  • Open Int (30-Day) 34,863

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.30
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +21.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8163 +69.06%
on 11/30/21
1.9200 -28.12%
on 12/03/21
+0.1800 (+15.00%)
since 11/05/21
3-Month
0.8163 +69.06%
on 11/30/21
1.9200 -28.12%
on 12/03/21
-0.0600 (-4.17%)
since 09/03/21
52-Week
0.8163 +69.06%
on 11/30/21
2.3075 -40.20%
on 04/15/21
-0.2000 (-12.66%)
since 12/04/20

Most Recent Stories

More News
Implied Volatility Surging for Ardelyx (ARDX) Stock Options

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

ARDX : 1.3800 (-9.21%)
Is a Surprise Coming for Ardelyx (ARDX) This Earnings Season?

Ardelyx (ARDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ARDX : 1.3800 (-9.21%)
Editas (EDIT) to Report Q3 Earnings: What's in the Cards?

On Editas' (EDIT) third-quarter earnings call, investor focus will likely be on the company's progress with the development of its lead pipeline candidate, EDIT-101.

ABBV : 121.35 (+2.10%)
ARDX : 1.3800 (-9.21%)
EDIT : 28.07 (+1.26%)
GMTX : 2.56 (+7.11%)
Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021

/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative...

ARDX : 1.3800 (-9.21%)
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

PCRX : 54.10 (+2.99%)
FLXN : 9.12 (-0.22%)
ARDX : 1.3800 (-9.21%)
GMTX : 2.56 (+7.11%)
Kessler Topaz Meltzer & Check, LLP:  Important Deadline Reminder for Ardelyx Inc. Investors in Securities Fraud Class Action Lawsuit

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased...

ARDX : 1.3800 (-9.21%)
CLASS ACTION UPDATE for ARDX, ANVS and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / September 28, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...

ARDX : 1.3800 (-9.21%)
ANVS : 20.97 (-3.01%)
SAVA : 43.96 (-4.12%)
SHAREHOLDER ALERT: ARDX LIVE SPPI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / September 28, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered...

ARDX : 1.3800 (-9.21%)
LIVE : 35.10 (+5.72%)
SPPI : 1.3800 (+0.73%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ardelyx, SelectQuote, Katapult, and Waterdrop Sciences and Encourages Investors to Contact the Firm

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders...

ARDX : 1.3800 (-9.21%)
SLQT : 9.33 (+5.78%)
KPLT : 2.85 (-0.35%)
WDH : 1.2600 (-8.03%)
LAWSUITS FILED AGAINST ARDX, HYRE and WDH - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / September 27, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

ARDX : 1.3800 (-9.21%)
HYRE : 4.82 (+3.21%)
WDH : 1.2600 (-8.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 2.0500
2nd Resistance Point 1.9000
1st Resistance Point 1.6400
Last Price 1.3800
1st Support Level 1.2300
2nd Support Level 1.0800
3rd Support Level 0.8200

See More

52-Week High 2.3075
Fibonacci 61.8% 1.7379
Fibonacci 50% 1.5619
Fibonacci 38.2% 1.3859
Last Price 1.3800
52-Week Low 0.8163

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar